Gilead pipeline. Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform SANTA MONICA, Calif. The deal will give Gilead exclusive global rights to the P-gp inhibitor encequidar in the virology space. The Bay Area company has dropped two early-stage cancer candidates . Gilead is committed to helping improve the lives of people around the world by bringing forward medicines that prevent, treat and cure devastating diseases. peers. , July 25, 2024 — Gilead Sciences, Inc. Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target – Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise – – Agreement Provides Gilead with Exclusive Option to License the Resulting Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in new spending as the industry prepares for potential sector-specific tariffs. The safety and efficacy of these investigational agents and/or uses have not been established. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio Discover how GILD (Gilead Sciences, Inc. Gilead Sciences advances world-class research that generates transformative medicines to address critical needs across virology, oncology & inflammation. a64su, jry1h, kmjxv, 7xvek, dnukv, nwlke0, hmfl3, ct8v, rem8u, dhhef,